Wide Ranks

AURA

Aura Biosciences, Inc.

9.00

Top Statistics
Market Cap 449 M Forward PE -4.43 Revenue Growth 0.00 %
Current Ratio 12.47 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.20 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 174 M Total Cash Per Share 3.49 Total Debt 19 M
Total Debt To Equity 10.93 Current Ratio 12.47 Book Value Per Share 3.51
All Measures
Short Ratio 416.00 % Message Board Id finmb_100249028 Shares Short Prior Month 1 M
Return On Equity -0.5099 City Boston Uuid 205d4b2f-04ec-3b66-84a0-9c2c5c015d78
Previous Close 8.96 First Trade Date Epoch Utc 1 B Book Value 3.51
Beta 0.3320 Total Debt 19 M Volume 285028
Price To Book 2.56 Fifty Two Week Low 6.63 Total Cash Per Share 3.49
Shares Short Previous Month Date 1 B Target Median Price 23.00 Audit Risk 7
Max Age 86400 Recommendation Mean 1.38 Sand P52 Week Change 0.3133
Target Mean Price 22.43 Net Income To Common -83216000 Short Percent Of Float 0.0257
Implied Shares Outstanding 50 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 292350 Average Volume10days 292350 Total Cash 174 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0508 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 8.96 Target Low Price 20.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 9.75 Open 9.01 Free Cashflow -47352500
State MA Dividend Yield 0.00 % Return On Assets -0.3022
Time Zone Short Name EST Board Risk 5 Trailing Eps -1.73
Day Low 8.91 Address1 80 Guest Street Shares Outstanding 49 M
Compensation Risk 8 Price Hint 2 Target High Price 24.00
Website https://www.aurabiosciences.com 52 Week Change 0.1222 Average Volume 196459
Forward Eps -2.03 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 1185.10 % Is_sp_500 False Regular Market Day High 9.11
Profit Margins 0.00 % Debt To Equity 10.93 Fifty Two Week High 12.38
Day High 9.11 Shares Short 947110 Regular Market Open 9.01
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0190 Operating Cashflow -73240000 Currency USD
Time Zone Full Name America/New_York Market Cap 449 M Is_nasdaq_100 False
Zip 02135 Quote Type EQUITY Industry Biotechnology
Long Name Aura Biosciences, Inc. Overall Risk 7 Regular Market Day Low 8.91
Held Percent Institutions 0.7757 Current Price 9.00 Address2 5th Floor
Enterprise To Ebitda -3.20 Financial Currency USD Current Ratio 12.47
Industry Disp Biotechnology Number Of Analyst Opinions 7 Country United States
Float Shares 34 M Two Hundred Day Average 8.42 Governance Epoch Date 1 B
Enterprise Value 294 M Forward PE -4.43 Regular Market Volume 285028
Ebitda -91836000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors.

The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer.

The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette–guérin therapy.

Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.